Non-pharmacological interventions play a big role in managing rheumatoid arthritis (RA) symptoms and improving quality of ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

The global market for Hemodialysis and Peritoneal Dialysis has exhibited a robust growth trajectory, with its valuation increasing from $15,681.81 million in 2019 to an anticipated $22,164.86 million ...